SOBI Swedish Orphan Biovitrum AB (publ)

Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of +77.27% and +39.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma to run the TELLOMAK-3 Phase 3 trial for lacutamab in cutaneous T cell lymphoma. See our latest analysis for Swedish Orphan Biovitrum. The lacutamab agreement lands after a softer month for Swedish Orphan Biovitrum’s share price, which is down about 3.4% over 30 days. However, the year-to-date share price return of 33.3% and 1-year total...

Swedish Orphan Biovitrum has delivered a strong share price run over the past five years, yet its current valuation checks lean expensive rather than cheap. For investors looking at the stock today, the key issue is how to balance that track record with a low overall value score and recent deal activity. The stock has returned 157.1% over five years, which puts a clear focus on whether recent gains already reflect much of Swedish Orphan Biovitrum's potential. The licensing agreement for...

Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare subset of CTCL.

Swedish Orphan Biovitrum AB (BIOVF) reports a robust 29% revenue growth, driven by key product performances and strategic pipeline advancements, despite facing competitive and regulatory challenges.